Anti-Obesity Pens: Understand Differences in Molecules, Categories and Rules
9 Articles
9 Articles
The Brazilian market for injectable medicines for diabetes and weight control is experiencing an accelerated expansion. With new approvals issued regularly by Anvisa (National Health Surveillance Agency), the supply of products has increased, but also
Records made by Anvisa in 2026 include semaglutide, liraglutide and new presentation of tirzepatide; prices vary
In 2026, the National Agency for Health Surveillance (Anvisa) expanded the options of injectable medicines used in the treatment of type 2 diabetes and obesity.The change occurred mainly after the end of the patent of the Ozempic, a medicine based on semaglutide (which helps control glucose) of the pharmaceutical company Novo Nordisk, in March. + Read more from Brazil in the West In all, 14 pens were approved by the agency this year: ten based o…
The National Agency of Health Surveillance this year expanded the range of injectable medicines used in the treatment of type 2 diabetes and obesity. 12 new pens were approved: ten based on semaglutide and two liraglutide. The movement gained strength after the end of the exclusivity of semaglutide in Brazil, on March 20, when [...]
Anvisa (National Health Surveillance Agency) this year expanded the options of injectable medicines used in the treatment of type 2 diabetes and obesity. Driven by the fall of the patent of the Ozempic (New Nordisk's Semaglutide) in March, the market received new generic and similar records of the substance, as well as new options based on [...]
The National Agency of Health Surveillance authorized 14 new injectable pens aimed at the treatment of type 2 diabetes and obesity in Brazil during the year 2026. The advance of the records comes from the end of the patent of Ozempic, produced by Novo Nordisk, expired on March 20, 2026. The set of approvals includes [...]
Coverage Details
Bias Distribution
- 100% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
